HOOKIPA Pharma Inc. (HOOK)
| Bid | 1.38 |
| Market Cap | 14.72M |
| Revenue (ttm) | 38.5M |
| Net Income (ttm) | -33.4M |
| EPS (ttm) | -3.67 |
| PE Ratio (ttm) | -0.42 |
| Forward PE | -0.87 |
| Analyst | Hold |
| Ask | 1.53 |
| Volume | 49,495 |
| Avg. Volume (20D) | 125,311 |
| Open | 1.48 |
| Previous Close | 1.50 |
| Day's Range | 1.45 - 1.57 |
| 52-Week Range | 1.45 - 10.50 |
| Beta | 0.70 |
About HOOK
HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase II clinical trial in patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-2...
Analyst Forecast
According to 3 analyst ratings, the average rating for HOOK stock is "Hold." The 12-month stock price forecast is $4.5, which is an increase of 195.08% from the latest price.
Next Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago · proactiveinvestors.co.uk
Gilead backs proposed Poolbeg Pharma's proposed tie-up with HOOKIPAGilead Sciences Inc (NASDAQ:GILD, ETR:GIS), the largest shareholder in HOOKIPA Pharma, has thrown its backing behind the proposed merger with Poolbeg Pharma PLC (AIM:POLB). Gilead, which holds just un...